Buy, Sell or Hold: Boston Scientific Corp (BSX-N) — Stock Predictions at Stockchase

skip to content

NYSE:BSX

38.14

0.07 (0.18%) 1d

Showing 1 to 15 of 48 entries

«
‹
1
2
3
4
›
»

Next Page

PAST TOP PICK

(A Top Pick Dec 01/20, Up 22%) Covid delayed surgeries. Labour shortages. Both are holding the stock back, but will improve. Solid, long-term core investment.

biotechnology / pharmaceutical

HOLD

Holds other healthcare plays. There is a good place for these names in portfolios. The organic growth from resuming treatment and surgeries will be interesting to follow. Wouldn't worry about the pullback.

biotechnology / pharmaceutical

WAIT

BSX vs. MDT Two great companies. In the implantable medical device business. Loves the area. Too expensive, as investors have flocked to them and the multiple has increased. Would love to own both if prices came down substantially.

biotechnology / pharmaceutical

BUY

Medical device maker. It has been a bit of a laggard. It was the market darling until 2019 and then they started to have a couple of misses and issues with products. He thinks these are all transient issues. He thinks in 2022 they will grow revenue in high single digits. He is going to stick with it and would buy it here.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Dec 01/20, Up 33%) He would buy it again. They had a decade of no-growth. In the last 3-5 years they introduced successful products that got their revenue going again. A lot of their procedures are not necessary today but will be over the next few months. The volumes are coming back. It is at the cheaper end of a lot of healthcare stocks.

biotechnology / pharmaceutical

BUY on WEAKNESS

It's one of Abbott's biggest competitors. It's in an attractive industry, medical equipment, where companies earn good returns. But BSX's valuation is high, gotten ahead of itself (like the whole sector), so wait for a pullback. BSX had a strong quarter as non-elective surgeries have bounced back, but its PE is rich.

biotechnology / pharmaceutical

PAST TOP PICK

(A Top Pick Jul 14/20, Up 23%) It had a couple of disappointing news items involving a couple of their products. They are playing catch-up on elective surgeries. It is one he really likes and continues to hold.

biotechnology / pharmaceutical

TOP PICK

It is a medical device company and people are starting to be able to get in to see their doctor and take care of things. A lot of their revenues are tied to non-deferrable procedures. That is positive for the whole group and they have company-specific catalysts also. (Analysts’ price target is $49.00)

biotechnology / pharmaceutical

HOLD

Looking at the longer term chart, they had a dip around the time China announced first cases of covid. Underperformed relative to others, like other mid-tech companies. Lots of procedures were delayed in hospitals. Now there will be catch up for this. At these levels, there is still some room to run. Could go to $48 range.

biotechnology / pharmaceutical

BUY

Hit a 52-week high today. This sector (medical devices) has reported very strong reports, such as Intuitive Surgical.

biotechnology / pharmaceutical

DON'T BUY

Liked it better in the past than today. If there were a recession, they'd need more capital. Remains a very fine company as to products. Good management that will learn from the past. Volumes in medical devices are not recovering as he expected. He owns Abbott Labs instead, a diversified player with a very strong balance sheet. You could also look at the dental space.

biotechnology / pharmaceutical

HOLD

Cardiovascular-related devices, and they're doing very well. Raised equity, and pulled a device from market due to potential safety issues. Took a bit of a hit on earnings. Likes it, but he's watching closely as it becomes more concentrated.

biotechnology / pharmaceutical

TOP PICK

One of the largest medical device manufacturers. New management has cleaned things up. Stock hit by a heart valve recall. Substantial upside. No dividend. (Analysts’ price target is $42.96)

biotechnology / pharmaceutical

BUY

It has been impacted. From 2013 to 2019 they could do no wrong, then there were a few hiccups. They discontinued one of their hard-valve products that will impact their growth over the next 3-4 years. If you think management can continue to execute and hit a couple of home runs, then stick with it. He would consider it a buy at these levels.

biotechnology / pharmaceutical

BUY

BSX vs. BDX Owns Boston Scientific instead of BDX. BSX has a strong history of execution. One-time events threw off that execution. Hospital procedures are coming back, which will benefit the entire industry. Well known for innovation.

biotechnology / pharmaceutical

Showing 1 to 15 of 48 entries

«
‹
1
2
3
4
›
»

Next Page

Boston Scientific Corp(BSX-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 6

Neutral - Hold Signals / Votes : 3

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 10

Stockchase rating for Boston Scientific Corp is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Boston Scientific Corp(BSX-N) Frequently Asked Questions

What is Boston Scientific Corp stock symbol?

Boston Scientific Corp is a American stock, trading under the symbol BSX-N on the New York Stock Exchange (BSX). It is usually referred to as NYSE:BSX or BSX-N

Is Boston Scientific Corp a buy or a sell?

In the last year, 10 stock analysts published opinions about BSX-N. 6 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Boston Scientific Corp.

Is Boston Scientific Corp a good investment or a top pick?

Boston Scientific Corp was recommended as a Top Pick by on . Read the latest stock experts ratings for Boston Scientific Corp.

Why is Boston Scientific Corp stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Boston Scientific Corp worth watching?

10 stock analysts on Stockchase covered Boston Scientific Corp In the last year. It is a trending stock that is worth watching.

What is Boston Scientific Corp stock price?

On 2021-12-01, Boston Scientific Corp (BSX-N) stock closed at a price of $38.14.

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : hello@stockchase.com.

© Stockchase Inc.